These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34089033)

  • 41. Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients.
    De Boeck I; Cauwenberghs E; Spacova I; Gehrmann T; Eilers T; Delanghe L; Wittouck S; Bron PA; Henkens T; Gamgami I; Simons A; Claes I; Mariën J; Ariën KK; Bakokimi D; Loens K; Jacobs K; Ieven M; Bruijning-Verhagen P; Delputte P; Coenen S; Verhoeven V; Lebeer S
    Microbiol Spectr; 2022 Oct; 10(5):e0168222. PubMed ID: 36154666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia.
    Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Ghweil AA; Sayed MAA; Rashad A; Mansour H; Abdelmaksoud AA
    Infect Drug Resist; 2022; 15():5483-5494. PubMed ID: 36164334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is the virus-laden standing water change the transmission intensity of SARS-CoV-2 after precipitation? A framework for empirical studies.
    He C; Wang X; Shui A; Zhou X; Liu S
    Environ Res; 2022 Dec; 215(Pt 1):114127. PubMed ID: 36041541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Control of exhaled SARS-CoV-2-laden aerosols in the interpersonal breathing microenvironment in a ventilated room with limited space air stability.
    Deng X; Gong G; He X; Shi X; Mo L
    J Environ Sci (China); 2021 Oct; 108():175-187. PubMed ID: 34465431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxypropyl Methylcellulose-Based Nasal Sprays Effectively Inhibit In Vitro SARS-CoV-2 Infection and Spread.
    Bentley K; Stanton RJ
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improving Nasal Protection for Preventing SARS-CoV-2 Infection.
    Nocini R; Henry BM; Mattiuzzi C; Lippi G
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
    Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS
    Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.
    Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Rashad A; Hassan RG; Abdelmaksoud AA
    Int J Nanomedicine; 2021; 16():4063-4072. PubMed ID: 34163159
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants.
    Kubale J; Gleason C; Carreño JM; Srivastava K; Singh G; ; Gordon A; Krammer F; Simon V
    mBio; 2022 Oct; 13(5):e0178422. PubMed ID: 35997286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses.
    Puhach O; Bellon M; Adea K; Bekliz M; Hosszu-Fellous K; Sattonnet P; Hulo N; Kaiser L; Eckerle I; Meyer B
    EBioMedicine; 2023 Dec; 98():104893. PubMed ID: 38035462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Saying no to SARS-CoV-2: the potential of nitric oxide in the treatment of COVID-19 pneumonia.
    Zhang H; Zhang C; Hua W; Chen J
    Med Gas Res; 2024; 14(2):39-47. PubMed ID: 37929506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection.
    Guerrieri M; Francavilla B; Fiorelli D; Nuccetelli M; Passali FM; Coppeta L; Somma G; Bernardini S; Magrini A; Di Girolamo S
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Westover JB; Ferrer G; Vazquez H; Bethencourt-Mirabal A; Go CC
    Cureus; 2020 Sep; 12(9):e10501. PubMed ID: 32963923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
    Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
    Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated.
    Lechien JR; Hoch CC; Vaira LA; Saussez S
    Am J Otolaryngol; 2021; 42(4):103008. PubMed ID: 33810883
    [No Abstract]   [Full Text] [Related]  

  • 57. Numerical evaluation of spray position for improved nasal drug delivery.
    Basu S; Holbrook LT; Kudlaty K; Fasanmade O; Wu J; Burke A; Langworthy BW; Farzal Z; Mamdani M; Bennett WD; Fine JP; Senior BA; Zanation AM; Ebert CS; Kimple AJ; Thorp BD; Frank-Ito DO; Garcia GJM; Kimbell JS
    Sci Rep; 2020 Jun; 10(1):10568. PubMed ID: 32601278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
    Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV
    Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.
    Khan MF; Ansari WA; Ahamad T; Khan MA; Khan ZA; Sarfraz A; Khan MA
    J Mol Model; 2022 Jul; 28(8):212. PubMed ID: 35794497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does Trypsin Oral Spray (Viruprotect
    Huijghebaert S; Vanham G; Van Winckel M; Allegaert K
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.